Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning tablets for CT myocardial perfusion in coronary heart disease with incomplete revascularization
ChiCTR2400088477Phase 4Not yet recruiting
- Sponsor
- Fuwai Central China Cardiovascular Hospital
- Start
- Aug 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Guanxinning in coronary arteriosclerosis, cardiac ischemia and angina pectoris (2 arms), sponsored by Fuwai Central China Cardiovascular Hospital. Primary endpoint: Change in CT myocardial perfusion after 6 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosiscardiac ischemiaangina pectoris
Beyond the preview
Go deeper on ChiCTR2400088477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088477.